Theme |
An up-to-date review of the molecular-targeted therapies for inflammatory bowel disease |
Title |
Treatment for IBD through the unique mode of action of vedolizumab |
Author |
Hirotake Sakuraba |
Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine |
Author |
Hiroto Hiraga |
Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine |
Author |
Keisuke Hasui |
Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine |
Author |
Hidezumi Kikuchi |
Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine |
Author |
Yasuhisa Murai |
Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine |
Author |
Shogo Kawaguchi |
Department of Vascular Biology, Hirosaki University Graduate School of Medicine |
Author |
Naoki Higuchi |
Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine |
Author |
Yui Akemoto |
Department of Anatomic Pathology, Hirosaki University Hospitaly |
Author |
Shinsaku Fukuda |
Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine / Hirosaki University |
[ Summary ] |
Vedolizumab(VDZ) is a new biological agent that blocks lymphocyte infiltration into the gut mucosa by binding to α4β7 integrin. Unlike conventional biologics targeting inflammatory cytokines, VDZ selectively controls gut immunity without systemic immunosuppression. Various studies have provided short- and long-term favorable effects of VDZ, as well as a low risk of serious infection and incidence of malignancies. Moreover, recent studies have indicated various predictors of favorable response to VDZ in conditions including perianal disease of Crohn's disease and extraintestinal manifestations. An improved knowledge of such predictors of response to therapy contributes to the appropriate selection of VDZ and the favorable outcome. |